NASDAQ · Biotechnology · USD

Inhibikase Therapeutics, Inc. (IKT) Stock Analysis

Inhibikase Therapeutics, Inc. (IKT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IKT

$2.50

−$0.02 (−0.79%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IKT with… →

IKT Key Statistics

As of Sep 4, 2026

Trading

Open: $2.49
Previous Close: $2.52
Day's Range: 2.48–2.55
52-Week Range: 1.33–2.61
Volume: 247.00K
Beta: 0.96

Valuation

Market Cap: $348.84M
P/E Ratio: unprofitable
EPS (ttm): −0.44

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$48.26M
Profit margin: 0.00%
Shares Outstanding: 139.54M
1-Year Return: +46.20%

Dividend and dates

Earnings Date: November 13, 2026estimated
Avg Volume: 775.42K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IKT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−30.30%−78.70%−65.99%−57.67%+155.91%−36.92%+21.95%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	+21.95%
2025	−36.92%
2024	+155.91%
2023	−57.67%
2022	−65.99%
2021	−78.70%
2020 (partial year)	−30.30%

As of September 4, 2026.

IKT Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$48.26M	—
2024	$0.00	−$27.52M	—
2023	$0.00	−$19.03M	—
2022	$0.00	−$18.05M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$53.35M	−$48.26M	—
2024	$0.00	—	−$28.59M	−$27.52M	—
2023	$0.00	—	−$20.09M	−$19.03M	—
2022	$0.00	—	−$18.13M	−$18.05M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IKT Valuation vs Biotechnology Median

Median of 656 stocks

Metric	IKT	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Inhibikase Therapeutics, Inc. (IKT) carries a market capitalisation of $348.84M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 35 employees.

The 52-week range on file runs from $1.33 to $2.61. The most recent close on file for IKT is $2.50, dated September 4, 2026. That is −$0.02 (−0.79%) against the previous close. The latest close sits 87.97% above that 52-week low.

Financial Health

In fiscal 2025, Inhibikase Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $48.26M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.44.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.96. Annualized volatility over the trailing 5 years is 94.05%. Over the trailing twelve months the price has returned +46.20%. Across 5 years the annualized return works out at −29.60%.

Growth & Income

No dividend is on file for IKT.

So far in 2026 the price is +21.95%. The strongest complete calendar year on file is 2024 at +155.91%; the weakest is 2021 at −78.70%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Inhibikase Therapeutics, Inc. (IKT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Inhibikase Therapeutics, Inc.	IKT	$348.84M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Inhibikase Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Visit website →